JNNP

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Janowicz, D M
Right arrow Articles by Gupta, S K
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Janowicz, D M
Right arrow Articles by Gupta, S K
Journal of Neurology Neurosurgery and Psychiatry 2005;76:891-892
© 2005 BMJ Publishing Group Ltd


LETTER

Successful treatment of CMV ventriculitis immune reconstitution syndrome

D M Janowicz, R M Johnson, S K Gupta

Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, IN 46202, USA

Correspondence to:
Correspondence to:
Dr Diane M Janowicz
dmjanowi@iupui.edu

Keywords: cytomegalovirus; ventriculitis; immune reconstitution syndrome

The first 150 words of the full text of this article appear below.


Successful treatment of CMV ventriculitis immune reconstitution syndrome
In HIV infected patients, cytomegalovirus (CMV) disease of the central nervous system is usually seen when the CD4+ count is less than 100 cells/mm3. Recommended treatment includes intravenous ganciclovir, foscarnet, or both.1 Ventriculitis is an uncommon but severe manifestation of CMV disease. Mortality is extremely high despite timely initiation of treatment. Little is known about CMV ventriculoencephalitis in the highly active antiretroviral therapy (HAART) era.


Case report
A 38 year old woman with no significant past medical history was diagnosed with Pneumocystis jiroveci (Pneumocystis carinii) pneumonia as her AIDS defining illness in April 2002. On 15 July 2002, HAART was initiated with zidovudine, lamivudine, and efavirenz. Her CD4+ count was 42 cells/mm3 and her HIV-1 RNA level was 95 000 copies/ml. Serum CMV IgG was positive.

Ten days later, she was evaluated for headache of new onset. Computed tomography (CT) of her head was unremarkable. Cerebrospinal fluid analysis showed no white . . . [Full text of this article]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.